Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
Open Access
- 20 May 2022
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2065824
Abstract
The emergence of different variants of SARS-CoV-2, including the Omicron (B.1.1.529) variant in November 2021, has resulted in a continuous major health concern at a global scale. Presently, the Omicron variant has spread very rapidly worldwide within a short time period. As the most mutated variant of SARS-CoV-2, Omicron has instilled serious uncertainties on the effectiveness of humoral adaptive immunity generated by COVID-19 vaccination or an active viral infection as well as the protection provided by antibody-based immunotherapies. Amidst such high public health concerns, the need to carry out booster vaccination has been emphasized. Current evidence reveals the importance of incorporating booster vaccination using several vaccine platforms, such as viral vector- and mRNA-based vaccines, as well as other platforms that are under explorative investigations. Further research is being conducted to assess the effectiveness and durability of protection provided by booster COVID-19 vaccination against Omicron and other SARS-CoV-2 variants.Keywords
Funding Information
- funding associated
This publication has 72 references indexed in Scilit:
- COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing PandemicArchives of Medical Research, 2021
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational studyThe Lancet Infectious Diseases, 2021
- Vaccine hesitancy in the era of COVID-19Public Health, 2021
- Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deploymentThe Lancet, 2021
- Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (Mpro): DFT, QSAR, molecular docking, and in silico toxicity analysisJournal of King Saud University – Science, 2021
- T cell response to SARS-CoV-2 infection in humans: A systematic reviewPLOS ONE, 2021
- Cell‐mediated immunity to SARS‐CoV‐2Pediatric Investigation, 2020
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityCell, 2020
- The importance of cell-mediated immunity in COVID-19 – An opinionMedical Hypotheses, 2020
- Cell-Mediated Immune Responses to COVID-19 InfectionFrontiers in Immunology, 2020